Deal Library / Pharma BD Deal Intelligence
Pharma Deals of 2026
The Pharma Closeout tracks 430 deals, $470.4B in disclosed deal value, 73 with a post-close Outcome Score for the year 2026.
Median Critic Score: 67 · Median Outcome Score: 61
Best outcome: Arcturus Therapeutics, Inc. / CSL Seqirus (CSL Limited) (100) · Weakest outcome: Merck & Co. Inc. / Protillion Biosciences, Inc. (48)
All 430 deals
- Arcturus Therapeutics, Inc. / CSL Seqirus (CSL Limited) — 2026 · $28M · Worked — the deal delivered on its rationale.
- Genentech, Inc. (Roche Group) / Duality Biologics (Suzhou) Co. Ltd. — 2026 · $1.0B · Worked — the deal delivered on its rationale.
- Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. — 2026 · $2.3B · Worked — the deal delivered on its rationale.
- Servier Pharmaceuticals LLC / Day One Biopharmaceuticals Inc. — 2026 · $2.5B · Worked — the deal delivered on its rationale.
- Servier / Edgewise Therapeutics, Inc. — 2026 · $2.6B · Worked — the deal delivered on its rationale.
- AstraZeneca PLC / Dizal Pharmaceutical Co., Ltd — 2026 · $1.5B · Largely worked — most objectives met.
- Travere Therapeutics, Inc. / Everest Medicines Limited — 2026 · $1.1B · Largely worked — most objectives met.
- AbbVie Inc. / Apogee Therapeutics, Inc. — 2026 · $10.9B · Largely worked — most objectives met.
- Pfizer Inc. / Innovent Biologics, Inc. — 2026 · $10.5B · Largely worked — most objectives met.
- BeOne Medicines Ltd. / Revolution Medicines — 2026 · Largely worked — most objectives met.
- GSK plc / Nuvalent, Inc. — 2026 · $10.6B · Largely worked — most objectives met.
- Fosun Wanbang Pharma Group / Shanghai Junshi Biosciences Co., Ltd. — 2026 · $187M · Largely worked — most objectives met.
- PTC Therapeutics Inc. / Sangamo Therapeutics, Inc. — 2026 · $211M · Largely worked — most objectives met.
- Novo Nordisk A/S / Vivtex Inc. — 2026 · $2.1B · Largely worked — most objectives met.
- Ipsen S.A. / Kartos Therapeutics, Inc. — 2026 · $1.8B · Largely worked — most objectives met.
- Swedish Orphan Biovitrum AB / Innate Pharma SA — 2026 · $580M · Largely worked — most objectives met.
- Vertex Pharmaceuticals Incorporated / Crinetics Pharmaceuticals, Inc. — 2026 · $10.0B · Largely worked — most objectives met.
- Incyte Corporation / Vega Therapeutics, Inc. — 2026 · $2.0B · Largely worked — most objectives met.
- Ipsen S.A. / Memo Therapeutics AG — 2026 · $797M · Largely worked — most objectives met.
- Rallybio Corporation / Avenzo Therapeutics Inc. — 2026 · $300M · Largely worked — most objectives met.
- argenx SE / Forte Biosciences, Inc. — 2026 · $2.2B · Largely worked — most objectives met.
- Sentynl Therapeutics, Inc. / Mereo BioPharma Group plc — 2026 · $475M · Largely worked — most objectives met.
- Johnson & Johnson / Sail Biomedicines, Inc. — 2026 · $3.4B · Largely worked — most objectives met.
- Eli Lilly and Company / Hanmi Pharmaceutical Co. Ltd. — 2026 · $1.3B · Largely worked — most objectives met.
- Oculis Holding AG / Accure Therapeutics S.L. — 2026 · $4M · Largely worked — most objectives met.
- Sanofi S.A. / Regeneron Pharmaceuticals, Inc. — 2026 · $8.0B · Largely worked — most objectives met.
- Sanofi SA / Sino Biopharmaceutical Ltd. — 2026 · $1.5B · Largely worked — most objectives met.
- Innovent Biologics, Inc. / Daiichi Sankyo Company, Limited — 2026 · Largely worked — most objectives met.
- Agios Pharmaceuticals Inc. / Oscotec Inc. — 2026 · $165M · Largely worked — most objectives met.
- Zymeworks Inc. / Theravance Biopharma, Inc. (TD-4208 program) — 2026 · $929M · Largely worked — most objectives met.
- Astellas Pharma Inc. / Sangamo Therapeutics, Inc. — 2026 · $50M · Largely worked — most objectives met.
- Novartis AG / Myricx Bio Ltd. — 2026 · $1.5B · Largely worked — most objectives met.
- Spero Therapeutics, Inc. / Innovent Biologics, Inc. — 2026 · $1.1B · Largely worked — most objectives met.
- Eli Lilly and Company / Ascidian Therapeutics, Inc. — 2026 · $1.9B · Largely worked — most objectives met.
- Novo Nordisk A/S / Jiangsu Hengrui Pharmaceuticals Co. Ltd. — 2026 · $2.6B · Largely worked — most objectives met.
- Regeneron Pharmaceuticals, Inc. / CytomX Therapeutics, Inc. — 2026 · $4.0B · Largely worked — most objectives met.
- Remix Therapeutics, Inc. / Passage Bio, Inc. — 2026 · $226M · Largely worked — most objectives met.
- AstraZeneca PLC / CSPC Pharmaceutical Group Ltd. — 2026 · $18.5B · Largely worked — most objectives met.
- Eli Lilly and Company / AtaiBeckley Inc. — 2026 · $3.8B · Largely worked — most objectives met.
- Gilead Sciences, Inc. / MacroGenics, Inc. — 2026 · $10M · Largely worked — most objectives met.
- Incyte Corporation / Halozyme Therapeutics, Inc. — 2026 · Largely worked — most objectives met.
- Novartis AG / Chai Discovery, Inc. — 2026 · Mixed — partial payoff, real shortfalls.
- United Therapeutics Corporation / Thymmune Therapeutics, Inc. — 2026 · $300M · Mixed — partial payoff, real shortfalls.
- Nuvectis Pharma, Inc. / Haisco Pharmaceutical Group Co., Ltd. — 2026 · $1.5B · Mixed — partial payoff, real shortfalls.
- Novartis AG / Orionis Biosciences, Inc. — 2026 · $1.4B · Mixed — partial payoff, real shortfalls.
- AstraZeneca PLC / CSPC Pharmaceutical Group Ltd. — 2026 · $1.8B · Mixed — partial payoff, real shortfalls.
- Johnson & Johnson / Firefly Bio, Inc. — 2026 · $1.0B · Mixed — partial payoff, real shortfalls.
- Serapha Bio, Inc. / Boundless Bio, Inc. — 2026 · $230M · Mixed — partial payoff, real shortfalls.
- Xiamen Amoytop Biotech Co., Ltd. / Aligos Therapeutics, Inc. — 2026 · $445M · Mixed — partial payoff, real shortfalls.
- Eli Lilly and Company / Haisco Pharmaceutical Group Co., Ltd. — 2026 · $3.1B · Mixed — partial payoff, real shortfalls.
- Genentech, Inc. (Roche Group) / Astex Pharmaceuticals — 2026 · $490M · Mixed — partial payoff, real shortfalls.
- Alnylam Pharmaceuticals Inc. / Inceptive Nucleics, Inc. — 2026 · $2.0B · Mixed — partial payoff, real shortfalls.
- Jasper Therapeutics, Inc. / Kira Pharmaceuticals — 2026 · Mixed — partial payoff, real shortfalls.
- Scancell Holdings plc / Neuphoria Therapeutics Inc. — 2026 · $25M · Mixed — partial payoff, real shortfalls.
- Mirador Therapeutics, Inc. / Kira Pharmaceuticals — 2026 · $12M · Mixed — partial payoff, real shortfalls.
- QuantumCell ApS / AlzeCure Pharma AB — 2026 · $2.2B · Mixed — partial payoff, real shortfalls.
- GSK plc / Suzhou Siran Biotechnology Co., Ltd. — 2026 · $1.1B · Mixed — partial payoff, real shortfalls.
- Eli Lilly and Company / Seamless Therapeutics GmbH — 2026 · $1.1B · Mixed — partial payoff, real shortfalls.
- Eli Lilly and Company / AlzeCure Pharma AB — 2026 · $1.0B · Mixed — partial payoff, real shortfalls.
- Boulevard Bio, Inc. / METiS TechBio — 2026 · $1.6B · Mixed — partial payoff, real shortfalls.
- Takeda Pharmaceutical Company Ltd. / Insilico Medicine Inc. — 2026 · $600M · Mixed — partial payoff, real shortfalls.
- Pfizer Inc. / Novavax Inc. — 2026 · $530M · Mixed — partial payoff, real shortfalls.
- Eli Lilly and Company / Sangamo Therapeutics, Inc. — 2026 · $50M · Mixed — partial payoff, real shortfalls.
- Galmed Pharmaceuticals Ltd. / Colospan Ltd. — 2026 · $4M · Mixed — partial payoff, real shortfalls.
- Orion Corporation / Shilpa Biologicals Private Limited — 2026 · Mixed — partial payoff, real shortfalls.
- Cartesian Therapeutics, Inc. / WestGene Biopharma Co., Ltd. — 2026 · Mixed — partial payoff, real shortfalls.
- Biogen Inc. / RayThera Inc. — 2026 · $1.0B · Mixed — partial payoff, real shortfalls.
- Teva Pharmaceutical Industries Ltd. / Samsung Bioepis Co., Ltd. — 2026 · Mixed — partial payoff, real shortfalls.
- Jazz Pharmaceuticals PLC / AbCellera Biologics Inc. — 2026 · $848M · Mixed — partial payoff, real shortfalls.
- Eli Lilly and Company / 4E Therapeutics, Inc. — 2026 · Mixed — partial payoff, real shortfalls.
- Merck & Co. Inc. / Protillion Biosciences, Inc. — 2026 · $510M · Mixed — partial payoff, real shortfalls.
- SK Biopharmaceuticals Co., Ltd. / Insilico Medicine Inc. — 2026 · $2.5B · Mixed — partial payoff, real shortfalls.
- China Medical System Holdings Limited / Insilico Medicine Inc. — 2026 · $165M · Mixed — partial payoff, real shortfalls.
- Royalty Pharma / Zealand Pharma A/S — 2026 · $100M
- Boehringer Ingelheim International GmbH / Variant Bio — 2026 · $250M
- Eli Lilly and Company / Repertoire Immune Medicines Inc. — 2026 · $1.9B
- Galera Therapeutics, Inc. / Obsidian Therapeutics — 2026
- Bayer AG / Perfuse Therapeutics, Inc. — 2026 · $2.5B
- Angelini Pharma S.p.A. / Catalyst Pharmaceuticals, Inc. — 2026 · $4.1B
- Dimerix Limited / Mission Therapeutics Ltd. — 2026 · $292M
- Armed Cell Therapeutics NV (ACTx) / Lakefront Biotherapeutics NV — 2026 · $239M
- Stipple Bio / Lonza — 2026
- InMed Pharmaceuticals Inc. / Mentari Therapeutics, Inc. — 2026 · $290M
- GSK plc / Chugai Pharmaceutical Co., Ltd. — 2026
- Sandoz Group AG / mAbxience — 2026
- Rose Pharma Inc. / MannKind Corporation — 2026
- Liminatus Pharma, Inc. / InnocsAI, Inc. — 2026 · $320M
- Orient EuroPharma / George Medicines — 2026
- XTL Biopharmaceuticals Ltd. / NeuroNOS — 2026
- Ampersand Biomedicines / Genethon — 2026
- Starpharma / Petalion Therapeutics Ltd. — 2026
- LG Chem / Frontier Medicines Corporation — 2026
- Mankind Pharma Limited / Armed Cell Therapeutics NV (ACTx) — 2026 · $56M
- Axogen, Inc. / BioCircuit Technologies, Inc. — 2026 · $200M
- R1 Therapeutics / Alebund Pharmaceuticals — 2026
- CSL Limited / Alentis Therapeutics AG — 2026 · $1.6B
- Grand Life Sciences / Belief BioMed — 2026
- Aurigene / Ers Genomics — 2026
- Taiwan Tanabe Seiyaku Co., Ltd. / Energenesis Biomedical Co., Ltd. — 2026
- Oruka Therapeutics, Inc. / Halozyme Therapeutics, Inc. — 2026
- SK Biopharmaceuticals Co., Ltd. / 1ST Biotherapeutics, Inc. — 2026 · $315M
- Orion Corporation / Qilu Pharmaceutical Group Co., Ltd. — 2026
- Lilly / Amplia Therapeutics Limited — 2026
- Bristol-Myers Squibb Company / Jiangsu Hengrui Pharmaceuticals Co. Ltd. — 2026 · $15.2B
- Gyre Therapeutics, Inc. / Cullgen — 2026 · $300M
- Helsinn Healthcare SA / InVirtuoLabs — 2026
- Zhejiang Conba Pharmaceutical Co., Ltd. / Adneuris Therapeutics, Inc. — 2026 · $118M
- Arrotex / Formosa Pharmaceuticals — 2026
- Novo Nordisk A/S / Ablexis, LLC — 2026
- Eli Lilly and Company / Vaccine Company, Inc. — 2026 · $1.6B
- Azurity Pharmaceuticals / PolyPid Ltd. — 2026 · $330M
- AstraZeneca PLC / Pinetree Therapeutics, Inc. — 2026 · $500M
- SK Biopharmaceuticals Co., Ltd. / Biohaven Pharmaceutical Holding Company Ltd. — 2026 · $795M
- COLLEGIUM PHARMACEUTICAL, INC / Corium Therapeutics — 2026
- Qilu Pharmaceutical Group Co., Ltd. / Insilico Medicine Inc. — 2026 · $120M
- Biogen Inc. / TJ Biopharma Co., Ltd. — 2026 · $850M
- Ona Therapeutics S.L. / WuXi XDC Cayman Inc. — 2026
- Lisata Therapeutics, Inc. / Marea Therapeutics — 2026
- Lilly / Repertoire — 2026
- Novartis AG / Unnatural Products, Inc. — 2026 · $1.8B
- Clayton, Dubilier & Rice, LLC / Option Care Health, Inc. — 2026 · $5.8B
- ARCHIMED (private equity) / Esperion Therapeutics Inc. — 2026 · $1.1B
- Formation Bio / Ctfh — 2026 · $500M
- Teva Pharmaceutical Industries Ltd. / BioXcel Therapeutics, Inc. — 2026 · $125M
- Engitix Therapeutics / Lonza Group AG — 2026
- Jupiter Neurosciences, Inc. / PharmAla Biotech Holdings Inc. — 2026 · $100M
- Sanofi / Earendil Labs — 2026
- Lotus Pharmaceutical Co., Ltd. / Alvotech — 2026 · $150M
- Treeline Biosciences, Inc. / Roche Holding AG — 2026
- AmyriAD Therapeutics, Inc. / Recognify Life Sciences, Inc. — 2026
- Tectora Therapeutics / Schrödinger, Inc. — 2026
- Jaguar LAA, Inc. / Johnson & Johnson — 2026
- Apotex Inc. / Cumberland Pharmaceuticals branded U.S. commercial business — 2026 · $100M
- Alembic Therapeutics, LLC / Exeltis USA, Inc. — 2026
- Rani Therapeutics Holdings, Inc. / PegBio Co., Ltd. — 2026
- Sanofi SA / Kali Therapeutics, Inc. — 2026 · $1.2B
- Amgen Inc. / Dark Blue Therapeutics Ltd. — 2026 · $840M
- Roche Holding AG / SAGA Diagnostics AB — 2026 · $595M
- Sino Biopharmaceutical Limited / GSK plc — 2026
- Eli Lilly and Company / Kelonia Therapeutics, Inc. — 2026 · $7.0B
- Eli Lilly and Company / QurCan Therapeutics Inc. — 2026 · $237M
- Junshi Biosciences / Antengene — 2026
- Maruishi Pharmaceutical / Adneuris Therapeutics — 2026
- LEO Pharma A/S / Tanabe Pharma Corporation — 2026 · $435M
- Agilent Technologies Inc. / Proscia Inc. — 2026 · $270M
- Pfizer Inc. / Enodia Therapeutics — 2026 · $500M
- Ahngook Pharmaceutical / George Medicines — 2026
- Tempus AI / Personalis, Inc. — 2026 · $1.5B
- Transgene / ProBioGen — 2026
- Neopharmed Gentili S.p.A. (Irish affiliate) / BioCryst Pharmaceuticals, Inc. — 2026 · $345M
- Servier / kyron.bio — 2026
- Multiplex Bio / Standard BioTools Inc. — 2026 · $10M
- Zydus Lifesciences Limited / Assertio Holdings, Inc. — 2026 · $166M
- CVC Capital Partners and Groupe Bruxelles Lambert consortium (Respighi BidCo S.p.A.) / Recordati S.p.A. — 2026 · $12.4B
- Roche Holding AG / Nurix Therapeutics Inc. — 2026 · $2.3B
- AstraZeneca PLC / Owkin, Inc. — 2026
- Seraxis Holdings, Inc. / Sernova Biotherapeutics — 2026
- Eli Lilly and Company / Profluent Bio — 2026 · $2.2B
- Halozyme Therapeutics, Inc. / Surf Bio, Inc. — 2026 · $400M
- STORM Therapeutics Ltd. / Alidabio — 2026
- Otsuka Pharmaceutical Co., Ltd. / Transcend Therapeutics, Inc. — 2026 · $1.2B
- Chiesi Group / KalVista Pharmaceuticals, Inc. — 2026 · $1.9B
- Gilead Sciences, Inc. / Vir Biotechnology Inc. — 2026 · $1.9B
- K2 Therapeutics / Antengene Corporation Limited — 2026 · $980M
- Regeneron Pharmaceuticals, Inc. / Parabilis Medicines, Inc. — 2026 · $2.3B
- Perceptive Advisors LLC / Ovid Therapeutics Inc. — 2026 · $294M
- Novartis AG / Abogen Biosciences Co., Ltd. — 2026 · $7.8B
- Novartis AG / BoomRay Pharmaceuticals — 2026 · $900M
- Eli Lilly and Company / Innovent Biologics, Inc. — 2026 · $8.8B
- Eli Lilly and Company / Curevo Vaccine, Inc. — 2026 · $1.5B
- Medicus Pharma Ltd. / Pfizer Inc. — 2026 · $1.0B
- Akari Therapeutics Plc / Whitehawk Therapeutics, Inc. — 2026
- Novo Nordisk A/S / Anthropic PBC — 2026
- BNC Korea / Leios Therapeutics — 2026
- Madrigal Pharmaceuticals / Arrowhead Pharmaceuticals Inc. — 2026 · $1.0B
- Novartis AG / Sironax Ltd. — 2026 · $125M
- Tenacia Biotechnology / Rapport Therapeutics, Inc. — 2026
- MacroGenics, Inc. / Sagard Healthcare Partners — 2026 · $80M
- Eisai Co., Ltd. / Henlius — 2026
- Slate Medicines, Inc. / Fulcrum Therapeutics, Inc. — 2026
- Ofichem Group / Kinentia Biosciences LLC — 2026
- AbbVie Inc. / Haisco Pharmaceutical Group Co., Ltd. — 2026 · $745M
- GlaxoSmithKline plc / Frontier Biotechnologies Inc. — 2026 · $1.0B
- Novo Nordisk A/S / Nanexa AB — 2026 · $1.3B
- Genentech, Inc. (Roche Group) / Earendil Labs, Inc. — 2026 · $1.5B
- Zealand Pharma A/S / Generate Biomedicines, Inc. — 2026 · $1.2B
- BeOne Medicines Ltd. / Huahui Health Ltd. — 2026 · $2.0B
- Sensei Biotherapeutics, Inc. / Faeth Therapeutics — 2026
- Merck & Co. Inc. / SciBrunch Therapeutics Co., Ltd. — 2026 · $2.1B
- Element Biosystems, LLC / Standard BioTools Inc. — 2026 · $6M
- UCB S.A. / Candid Therapeutics, Inc. — 2026 · $2.2B
- Everest Medicines Limited / Dimerix Limited — 2026 · $340M
- Novartis AG / SciNeuro Pharmaceuticals — 2026 · $1.7B
- Gilead Sciences Inc. / Ouro Medicines, Inc. — 2026 · $2.2B
- CSPC Pharmaceutical Group Ltd. / AstraZeneca PLC — 2026
- Novo Nordisk A/S / Kallyope Inc. — 2026
- Biogen Inc. / Apellis Pharmaceuticals, Inc. — 2026 · $5.6B
- Novartis AG / Excellergy, Inc. — 2026 · $2.0B
- Eli Lilly and Company / Insilico Medicine Inc. — 2026 · $2.8B
- Arrotex Pharmaceuticals / LENZ — 2026
- Everest Medicines / LENZ — 2026
- Servier / Owkin, Inc. — 2026
- Teva Pharmaceutical Industries Ltd. / Samsung Bioepis Co., Ltd. — 2026
- Roche Holding AG / Dualitas Therapeutics, Inc. — 2026 · $1.0B
- F. Hoffmann-La Roche AG / MediLink Therapeutics (Suzhou) Co., Ltd. — 2026 · $570M
- Boehringer Ingelheim International GmbH / Envisagenics, Inc. — 2026 · $1.0B
- Primevera Therapeutics LLC / Foresee Pharmaceuticals — 2026
- Tarsus Pharmaceuticals / Alkeus Pharmaceuticals, Inc. — 2026 · $800M
- Heron Therapeutics, Inc. / Long Grove Pharmaceuticals, LLC — 2026
- BCM Europe AG / OSR Holdings, Inc. — 2026 · $815M
- Pathos AI, Inc. / Jiangsu Alphamab Biopharmaceuticals Co., Ltd. — 2026 · $2.2B
- Eli Lilly and Company / OmniAb, Inc. — 2026 · $370M
- Pharmanovia / Impact Therapeutics, Inc. — 2026
- Nippon Kayaku Co., Ltd. / GlycoNex, Inc. — 2026
- Alnylam Pharmaceuticals / Tenaya — 2026
- Amgen Inc. / DISCO Pharmaceuticals AG — 2026 · $618M
- Bristol-Myers Squibb Company / Janux Therapeutics — 2026 · $850M
- Phoenix Asia Holdings Limited / ACEA Pharma, Inc. (subsidiary of ACEA Therapeutics / Scilex Holding Company) — 2026 · $1.0B
- Merck & Co. Inc. / Infinimmune, Inc. — 2026 · $838M
- BioSyent Inc. / Oral Science Inc. — 2026
- Whitehawk Therapeutics, Inc. / Hangzhou DAC Biotech Co., Ltd. — 2026
- Sentivera, Inc. / Haisco Pharmaceutical Group Co., Ltd. — 2026 · $1.5B
- KKR & Co. Inc. / Integer Holdings Corporation — 2026 · $5.7B
- Boehringer Ingelheim International GmbH / Immunitas Therapeutics, Inc. — 2026
- Indivior PLC / Supernus Pharmaceuticals, Inc. — 2026 · $3.4B
- Boehringer Ingelheim / Variant Bio — 2026
- Regeneron Pharmaceuticals, Inc. / Telix Pharmaceuticals Limited — 2026 · $2.1B
- Boehringer Ingelheim International GmbH / Immunai Inc. — 2026 · $15M
- GSK plc / HUTCHMED (China) Limited — 2026 · $1.3B
- JW Pharmaceutical Corporation / Gan & Lee Pharmaceuticals Co., Ltd. — 2026 · $81M
- Biossil, Inc. / Summit Therapeutics plc — 2026 · $104M
- Sentynl Therapeutics, Inc. / PRG S&T — 2026
- Avere Therapeutics / Hansoh Pharmaceutical Group Co. Ltd. — 2026 · $2.3B
- Processa Pharmaceuticals, Inc. / Vidya Therapeutics, Inc. — 2026
- Skye Bioscience, Inc. / Redx Pharma Ltd — 2026
- Servier / Vect-Horus — 2026
- GSK plc / 35Pharma Inc. — 2026 · $950M
- B-FLEXION Life Sciences / Radius Health — 2026
- Royalty Pharma / Neurimmune AG (NI006 license) — 2026 · $425M
- Oak Hill Bio (OHB Pediatrics Ltd.) / Research Alliance Corporation III — 2026 · $175M
- Eli Lilly and Company / BioArctic AB — 2026 · $800M
- Shanghai Henlius Biotech, Inc. / Amberstone Biosciences, Inc. — 2026 · $888M
- SERB Pharmaceuticals SA / Hansa Biopharma AB — 2026 · $134M
- Aethlon Medical, Inc. / North Immunology, Inc. — 2026
- Gilead Sciences Inc. / Arcellx, Inc. — 2026 · $7.8B
- MeiraGTx Holdings plc / Johnson & Johnson (Janssen Pharmaceuticals) — 2026 · $25M
- Taisho Pharmaceutical Co., Ltd. / Kaigene, Inc. — 2026
- Lilly / Vaccine Company — 2026 · $1.6B
- SK bioscience / Gates Medical Research Institute — 2026
- Link Cell Therapies / Nona Biosciences — 2026
- Ligand Pharmaceuticals Incorporated / XOMA Royalty Corporation — 2026 · $739M
- GSK plc / RAPT Therapeutics, Inc. — 2026 · $2.2B
- Shionogi & Co., Ltd. / IntraBio Inc. — 2026 · $2.0B
- Shanghai Lishan Biopharmaceuticals Co. / Evogene Ltd. — 2026
- Ambros Therapeutics, Inc. / Werewolf Therapeutics, Inc. — 2026 · $150M
- Viatris / Pacira BioSciences, Inc. — 2026 · $1.6B
- AbbVie Inc. / RemeGen Co., Ltd. — 2026 · $5.6B
- Pathos AI, Inc. / DeuterOncology N.V. — 2026
- CMS / Insilico Medicine — 2026
- Ono Pharmaceutical / Scenic Biotech — 2026
- Roche Holding AG / Simcere Zaiming Pharmaceutical Co., Ltd. — 2026 · $1.5B
- Lilly / Centessa Pharmaceuticals — 2026
- Eli Lilly and Company / LimmaTech Biologics AG — 2026 · $780M
- OliX Pharmaceuticals / Vect-Horus — 2026
- Roots Pharmaceutical / Ocugen, Inc. — 2026 · $259M
- Ampersand Capital Partners / Purna Pharmaceuticals — 2026
- Nippon Shinyaku / Elixirgen Therapeutics, Inc. — 2026
- Eli Lilly and Company / InnoCare Pharma Limited — 2026 · $3.4B
- Odyssey Therapeutics, Inc. / Evotec SE — 2026
- Eli Lilly and Company / Engage Biologics, Inc. — 2026 · $202M
- Hebei Senlang Biotechnology Co., Ltd. / Tempest Therapeutics, Inc. — 2026
- Chia Tai Tianqing Pharmaceutical Group (subsidiary of Sino Biopharmaceutical Limited) / GSK plc — 2026
- Avere Therapeutics / NextCure, Inc. — 2026
- Gc Biopharma / Osivax — 2026
- AstraZeneca PLC / Modella AI, Inc. — 2026
- Takeda Pharmaceutical Company Ltd. / Iambic Therapeutics, Inc. — 2026 · $1.7B
- Genentech, Inc. (Roche Group) / MaxCyte, Inc. — 2026
- 20/20 BioLabs, Inc. / ROKIT Healthcare — 2026
- ZipBio / MeiraGTx — 2026
- Lee's Pharmaceutical Limited / 1cBio, Inc. — 2026 · $27M
- IQVIA Holdings Inc. / Medera Inc. — 2026
- Biodexa Pharmaceuticals PLC / Otsuka — 2026
- Eli Lilly and Company / Merida Biosciences, Inc. — 2026 · $2.9B
- Sun Pharmaceutical Industries Ltd. / Organon & Co. — 2026 · $11.8B
- Teva Pharmaceutical Industries Ltd. / Polpharma Biologics International AG — 2026
- Apotex / Grünenthal — 2026
- Teva Pharmaceutical Industries Ltd. / Emalex Biosciences, Inc. — 2026 · $900M
- Piramal Pharma Limited / Yapan Bio Private Limited — 2026 · $8M
- Recordati / Moderna — 2026
- Roche Holding AG / PathAI, Inc. — 2026 · $1.1B
- Gilead / Galapagos — 2026
- GSK plc / Relation Therapeutics Limited — 2026 · $110M
- Samsung Biologics Co., Ltd. / PolyPeptide Group AG — 2026 · $1.8B
- Jamjoom Pharmaceuticals Factory Co. / Idorsia Pharmaceuticals Ltd. — 2026
- MS Pharma Group / Hetero — 2026
- Sidewinder Therapeutics / Synaffix B.V. — 2026
- Hygtia Therapeutics Co., Ltd. / Insilico Medicine Inc. — 2026 · $66M
- Esperion Therapeutics Inc. / Corstasis Therapeutics, Inc. — 2026 · $255M
- Tarsus Pharmaceuticals, Inc. / iRenix Medical — 2026
- Incyte Corporation / Genesis Molecular AI, Inc. — 2026 · $1.0B
- Sanofi SA / Chia Tai Tianqing Pharmaceutical Group (subsidiary of Sino Biopharmaceutical Limited) — 2026 · $1.5B
- Eli Lilly and Company / Gate Bioscience — 2026 · $870M
- Vasque Bio / Laekna Limited — 2026 · $527M
- Ono Pharmaceutical Co., Ltd. / Biohaven Ltd. — 2026
- Repligen Corporation / BioLife Solutions, Inc. — 2026 · $1.5B
- Novartis AG / Antares Therapeutics, Inc. — 2026 · $1.9B
- Chong Kun Dang Pharmaceutical Corporation / Kiora Pharmaceuticals, Inc. — 2026
- AstraZeneca / AbelZeta Pharma, Inc. — 2026 · $630M
- Roche Holding AG / Atavistik Bio — 2026 · $2.0B
- UCB S.A. / Neurona Therapeutics, Inc. — 2026 · $1.1B
- Amneal Pharmaceuticals Inc. / Kashiv BioSciences LLC — 2026 · $1.1B
- Roche Holding AG / C4 Therapeutics, Inc. — 2026 · $1.0B
- Ribo / Insilico Medicine — 2026
- Eli Lilly and Company / Abbisko Therapeutics Co., Ltd. — 2026 · $1.9B
- Eli Lilly and Company / Centessa Pharmaceuticals plc — 2026 · $7.8B
- Everest Medicines Limited / Beijing Mabworks Biotech Co., Ltd. — 2026
- Molecular Partners / Eckert & Ziegler — 2026
- Eli Lilly and Company / Amplitude Therapeutics, Inc. — 2026
- Elaris FlexCo / Valneva — 2026
- Eledon Pharmaceuticals / NewcelX Ltd. — 2026
- F. Hoffmann-La Roche AG / Hansoh Pharmaceutical Group Co. Ltd. — 2026 · $15.5B
- Asahi Kasei Life Science Corporation / The Noguchi Institute — 2026
- Madrigal Pharmaceuticals / Suzhou Ribo Life Science Co., Ltd. — 2026 · $4.4B
- Servier / Insilico Medicine — 2026 · $888M
- Eli Lilly and Company / Ajax Therapeutics, Inc. — 2026 · $2.3B
- Tolerance Bio, Inc. / Tanabe Pharma Corporation — 2026 · $560M
- Pfizer Inc. / Chai Discovery, Inc. — 2026
- Erasca, Inc. / Tango Therapeutics — 2026
- GE HealthCare / SOFIE Biosciences, Inc. — 2026 · $945M
- Bristol Myers Squibb / Oxford BioTherapeutics — 2026
- Curium U.S. Holdings LLC / Lantheus Holdings, Inc. — 2026 · $8.0B
- Context Therapeutics Inc. / BioAtla, Inc. — 2026 · $6M
- Menarini Group / Gan & Lee Pharmaceuticals Co., Ltd. — 2026 · $843M
- Labcorp / BioReference Health — 2026 · $872M
- Skye Bioscience, Inc. / Halozyme Therapeutics, Inc. — 2026
- CARsgen Therapeutics / Dispatch Bio — 2026
- Biogen Inc. / Alloy Therapeutics, Inc. — 2026
- GNI Group Ltd. / Ayumi Pharmaceutical Holdings Co., Ltd. — 2026
- Akeso Inc. / INOVIO — 2026
- PRISM BioLab Co., Ltd. / Receptor.AI Inc. — 2026
- Actimed Therapeutics Ltd / Faraday Pharmaceuticals, Inc. — 2026
- Bayer / Cradle — 2026
- Boehringer Ingelheim International GmbH / Sitryx Therapeutics Ltd. — 2026 · $500M
- AbbVie Inc. / Iambic Therapeutics, Inc. — 2026
- CSL Limited / Memo Therapeutics AG — 2026 · $328M
- Chugai Pharmaceutical Co. Ltd. / Araris Biotech AG — 2026 · $780M
- Treeline Biosciences, Inc. / Standard BioTools Inc. — 2026
- Nxera Pharma Co. Ltd / Santhera — 2026
- Eli Lilly and Company / CSL Limited — 2026 · $100M
- Theramex / Asieris Pharmaceuticals — 2026 · $250M
- Eli Lilly and Company / AC Immune SA — 2026
- Boehringer Ingelheim / Jazz Pharmaceuticals — 2026
- Sandoz Group AG / Shanghai Henlius Biotech, Inc. — 2026 · $322M
- BioMarin Pharmaceutical Inc. / Alesta Therapeutics B.V. — 2026 · $490M
- Fresenius SE / Fresenius Kabi / mAbxience — 2026 · $850M
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. / AriBio Co., Ltd. — 2026 · $240M
- AstraZeneca PLC / insitro — 2026 · $1.5B
- Fosun Kairos / ElpasBio Holdings — 2026
- Grünenthal GmbH / Bayer AG — 2026 · $431M
- Sandoz AG / Samsung Bioepis Co., Ltd. — 2026
- Neurocrine Biosciences Inc. / Soleno Therapeutics, Inc. — 2026 · $2.9B
- MeiraGTx / J&J — 2026
- Lupin Limited / Tenpoint Therapeutics, Inc. — 2026
- Telix Pharmaceuticals Limited / ITM Isotope Technologies Munich SE — 2026 · $1.6B
- Gilead Sciences Inc. / Tubulis GmbH — 2026 · $5.0B
- Rigel Pharmaceuticals, Inc. / Arvinas, Inc. / Pfizer Inc. — 2026 · $405M
- GSK plc / Halozyme Therapeutics, Inc. — 2026
- Merck / Quotient — 2026 · $2.2B
- Everest Medicines Limited / Corxel Pharmaceuticals — 2026
- Nordic Capital / BWXT Medical Ltd. — 2026 · $800M
- Praxis Precision Medicines, Inc. / Remagine Labs — 2026
- Vertex / WuXi Biologics — 2026
- GSK plc / Chimagen Biosciences — 2026 · $750M
- AstraZeneca PLC / Chia Tai Tianqing Pharmaceutical Group (subsidiary of Sino Biopharmaceutical Limited) — 2026 · $1.9B
- Cue Biopharma, Inc. / Ascendant Health Sciences Ltd. (Ascendant-221) — 2026 · $692M
- Evogene Ltd. / Unravel Biosciences — 2026
- Eli Lilly and Company / CrossBridge Bio, Inc. — 2026 · $300M
- Eli Lilly and Company / METiS TechBio — 2026 · $1.1B
- Recordati S.p.A. / Ionis Pharmaceuticals, Inc. — 2026
- Astellas Pharma Inc. / Vir Biotechnology — 2026
- Pulmatrix, Inc. / Eos SENOLYTIX — 2026
- Enodia Therapeutics / Kezar Life Sciences — 2026 · $128M
- Bio Usawa / Nanoly Bioscience — 2026 · $500M
- Merck KGaA / Silence Therapeutics plc — 2026 · $1.1B
- Eurobio Scientific / CareDx Lab Products business — 2026 · $170M
- Jazz Pharmaceuticals PLC / Actio Biosciences, Inc. — 2026 · $1.3B
- Samil Pharmaceuticals / Formosa Pharmaceuticals — 2026
- Roche Holding AG / Defand Therapeutics — 2026 · $1.0B
- GSK plc / Chai Discovery, Inc. — 2026
- McKesson Corporation / Precision Medicine Group, LLC — 2026 · $2.2B
- Xiamen Amoytop Biotech Co., Ltd. / Aligos Therapeutics, Inc. — 2026 · $445M
- Eli Lilly and Company / Orna Therapeutics, Inc. — 2026 · $2.4B
- Novartis AG / Alteogen — 2026 · $3.2B
- Genentech / Alector, Inc. — 2026 · $1.3B
- Bristol Myers Squibb / Chai Discovery, Inc. — 2026
- Pathos AI, Inc. / AstraZeneca PLC — 2026
- Tolerance Bio, Inc. / NeoImmuneTech, Inc. — 2026 · $260M
- Bcworld Pharm / Grünenthal — 2026
- LEO Pharma A/S / Replay Holdings LLC — 2026 · $50M
- Eli Lilly and Company / Ventyx Biosciences, Inc. — 2026 · $1.2B
- Aptevo Therapeutics Inc. / Niowave, Inc. — 2026
- Merck & Co. Inc. / Terns Pharmaceuticals, Inc. — 2026 · $6.7B
- Novartis AG / Pikavation Therapeutics, Inc. — 2026 · $3.0B
- Merck KGaA / Bio-Techne Corporation — 2026 · $11.3B
- Elaris FlexCo / Matrivax — 2026
- CORE Biomedicine, Inc. / Eisai Co., Ltd. — 2026
- Galderma Group AG / ZO Skin Health, Inc. — 2026 · $1.5B
- Cellution Biologics Inc. / Elutia Inc. — 2026 · $11M
- UCB S.A. / Antengene Corporation Limited — 2026 · $1.2B
- Recursion Pharmaceuticals, Inc. / Tempus AI — 2026 · $42M
- Pierre Fabre Laboratories / Iktos — 2026
- Scipher Medicine / Chemomab Therapeutics Ltd. — 2026
- Alfasigma S.p.A. / GlaxoSmithKline plc — 2026 · $690M
- Alaunos Therapeutics, Inc. / Velaris Therapeutics, Inc. — 2026
- DRI Healthcare Trust / Bain Capital / NovaQuest Capital Management (tavapadon royalty funds) — 2026 · $316M
- Lilly / Seamless Therapeutics — 2026
- Tolmar / Alpha Tau Medical LTD. — 2026
- Webster Equity Partners / Lifecore Biomedical, Inc. — 2026 · $664M
- Arrotex / George Medicines — 2026
- Roche Holding AG / Rona Therapeutics — 2026 · $1.2B
- Kyoritsu Seiyaku / bitBiome, Inc. — 2026
- Yatiri Bio, Inc. / Oscotec — 2026
- AbbVie Inc. / Kestrel Therapeutics, Inc. — 2026 · $1.4B
- Novo Nordisk A/S / Orbis Medicines ApS — 2026 · $1.4B
- Novartis AG / Zonsen PepLib Biotech Inc. — 2026
- Quince Therapeutics, Inc. / Orphai Therapeutics Inc. — 2026
- Kuva Labs, Inc. / Lisata Therapeutics, Inc. — 2026
- Coherus Oncology, Inc. / Zumutor Biologics — 2026
- Biogen / Alteogen — 2026
- Transgene / NEC Bio — 2026
← Deal Library ·
Interactive search ·
How we score deals